Technology
Phi Pharma technology differentiation resides in providing a peptide alternative to Antibody-Drug-Conjugates (ADC) with a new paradigm: “high capacity / tailored affinity”. In addition to Phi Pharma IP around the peptide platform, Phi Pharma offers the opportunity to leverage the IP of existing active ingredients.
Phi Pharma intracellular targeting technology transforms drug potency by targeting therapeutic molecules inside a range of different tumour cells and certain activated white blood cells. Initial Phi Pharma targeting peptides have been optimised for cell specific binding and high capacity delivery into leucocyte tumours and activated leukocyte subsets. These properties allow increased drug concentration inside targeted cells while sparing off-target cell side-effects. Peptide-drug conjugates are designed for improved pharmacokinetic properties and uncoupling of the drug inside the target cells.
Phi Pharma intracellular targeting technology transforms drug potency by targeting therapeutic molecules inside a range of different tumour cells and certain activated white blood cells. Initial Phi Pharma targeting peptides have been optimised for cell specific binding and high capacity delivery into leucocyte tumours and activated leukocyte subsets. These properties allow increased drug concentration inside targeted cells while sparing off-target cell side-effects. Peptide-drug conjugates are designed for improved pharmacokinetic properties and uncoupling of the drug inside the target cells.